{"id":128324,"date":"2022-03-23T07:27:20","date_gmt":"2022-03-23T11:27:20","guid":{"rendered":"https:\/\/44.250.171.167\/?p=128324"},"modified":"2022-10-05T06:19:07","modified_gmt":"2022-10-05T10:19:07","slug":"aurobindo-pharma-q3-fy-2022-research-tear-sheet","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q3-fy-2022-research-tear-sheet\/","title":{"rendered":"Aurobindo Pharma Q3 FY 2022 Research Tear Sheet"},"content":{"rendered":"\n

Aurobindo Pharma Limited is an Indian pharmaceutical company. It is based in  HITEC City, Hyderabad, India. It was incorporated in 1986. The pharmaceutical products include generic drugs, over-the-counter drugs, vaccines<\/a>, diagnostics, contact lenses and animal health. The company markets its products in more 125+ countries by Pfizer and AstraZeneca plc. The shares are traded both on BSE and NSE.<\/p>\n\n\n\n

Key Financial Highlights<\/u><\/strong><\/p>\n\n\n\n

Amount (INR Cr)<\/td>Q3FY22<\/td>Q3FY21<\/td><\/tr>
Revenue from operations<\/td>6,002.20<\/td>6,064.80<\/td><\/tr>
EBITDA before Forex and Other income<\/td>1,016.30<\/td>1,280.70<\/td><\/tr>
Net Profit<\/td>604.3<\/td>777.3<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Revenue from Operations at INR 6,002 Cr declined by 1% Y-O-Y.<\/p>\n\n\n\n

Research & Development (R&D) spend is 6.6% of revenues i.e.  INR 393 Cr.<\/p>\n\n\n\n

Net Profit stood at INR 604.3 Cr compared to INR 777.3 Cr.<\/p>\n\n\n\n

Basic & Diluted EPS is INR 10.32 per share.<\/p>\n\n\n\n

EBIDTA before Forex and Other income stood at INR 1,016.3 Cr.<\/p>\n\n\n\n

The EBITDA margin for the quarter is  16.9%<\/p>\n\n\n\n

Cash Position:<\/u><\/strong><\/p>\n\n\n\n

The company has generated a free cash flow of $ 201 in Q3 FY 2022. The working capital reduced with the reduction of inventory. However the strong cash position has helped the company to improve the investment.<\/p>\n\n\n\n

US Formulations:<\/u><\/strong><\/p>\n\n\n\n

In Q3 FY22, US revenue decreased by 4.4% YoY to INR 2,745.2 Cr. The company has filed for  10 ANDAs including 3 Injectables with USFDA in Q3 FY22. Received final approval for 4 ANDAs including 1 injectable product in Q3 FY22. The company has launched 7 products during the quarter, including 4 Injectables. It is the largest generics Company in the US by Rx dispensed.<\/p>\n\n\n\n

Europe Formulations<\/u><\/strong><\/p>\n\n\n\n

The revenue is INR 1,694.3 Cr, increased 1.4% YoY.  The total revenue consolidates 28% from Europe.<\/p>\n\n\n\n

ARV Formulations<\/u><\/strong><\/p>\n\n\n\n

ARV business revenue declined by 64.9% YoY to INR 155.7 Cr. There has been an improvement 7.4% QoQ.<\/p>\n\n\n\n

Growth Markets Formulations<\/u><\/strong><\/p>\n\n\n\n

Revenue from Growth Markets formulations are flat on a YoY basis and increased 2.8% QoQ to INR 397 Cr.<\/p>\n\n\n\n

Active Pharmaceutical Ingredients (API)<\/u><\/strong><\/p>\n\n\n\n

API business posted revenue of INR 1,010.0 Cr. and contributed 16.8% of the consolidated revenues.<\/p>\n\n\n\n

Conference Call Highlights<\/u><\/strong><\/p>\n\n\n\n

Management updates<\/u><\/strong><\/p>\n\n\n\n

The gross debt is $ 499 million reduced quarter-on-quarter basis.<\/p>\n\n\n\n

Net working capital for the quarter has been reduced by $ 137 million.<\/p>\n\n\n\n

Net organic CAPEX for the quarter is around $ 52 million.<\/p>\n\n\n\n

Revenue of Auromedics, injectable business declined  by 7% year-on-year to 63.2 million for Q3 FY 2022.<\/p>\n\n\n\n

For Q3 FY 2022 Growth Market witnessed a growth of 2.8% quarter on-quarter to Rs. 397 crores.<\/p>\n\n\n\n

Business Updates<\/u><\/strong><\/p>\n\n\n\n

Aurobindo Pharma Managing Director N Govindarajan resigns from his position.<\/p>\n\n\n\n

Aurobindo Pharma appoints  K Nithyananda Reddy as managing director.
Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck’s molnupiravir.<\/p>\n\n\n\n

Aurobindo Pharma has appointed Chief Operating Officer for API vertical.<\/p>\n","protected":false},"excerpt":{"rendered":"

Aurobindo Pharma Limited is an Indian pharmaceutical company. It is based in  HITEC City, Hyderabad, India. It was incorporated in 1986. The pharmaceutical products include generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses and animal health. The company markets its products in more 125+ countries by Pfizer and AstraZeneca plc. The shares are traded both on BSE and […]<\/p>\n","protected":false},"author":1796,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6352,9908],"tags":[9138,1115],"class_list":["post-128324","post","type-post","status-publish","format-standard","hentry","category-research-summary","category-research-tear-sheet","tag-pharma","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":133199,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy-2023-research-tear-sheet\/","url_meta":{"origin":128324,"position":0},"title":"Aurobindo Pharma Limited Q1 FY 2023 Research Tear Sheet","author":"sreerupa","date":"August 15, 2022","format":false,"excerpt":"Stock Data Ticker: AUROPHARMA Exchange :NSE and BSE Industry: Automobile Price Performance Last 7 days\u00a0\u00a0\u00a0 4.36% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -19.19% Last 12 months\u00a0\u00a0\u00a0\u00a0 -28.17% It will be beneficial to invest in the stocks of Aurobindo Pharma. The company enjoys a \u00a0healthy\u00a0ROE of\u00a021.49% ROE which is an\u00a0 important financial parameter. The company has\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130478,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q4-fy-2022-research-tear-sheet\/","url_meta":{"origin":128324,"position":1},"title":"Aurobindo Pharma Q4 FY 2022 Research Tear Sheet","author":"sreerupa","date":"June 6, 2022","format":false,"excerpt":"Aurobindo Pharma Limited is an Indian pharmaceutical company. It was established in the year 1986. The founders include Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals. The company started its operation in the year 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":148570,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-driving-growth-in-the-pharmaceutical-industry\/","url_meta":{"origin":128324,"position":2},"title":"Aurobindo Pharma: Driving Growth in the Pharmaceutical Industry","author":"Divyansh_Kasana","date":"June 8, 2023","format":false,"excerpt":"Stock Data: TickerNSE: AUROPHARMAExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+2.46%YTD+54.04%Last 12 Months+26.40% Company Description: Aurobindo, a company based in Hyderabad since 1986, focuses on producing generic formulations and APIs. Most of Aurobindo's sales, around 90%, come from international markets. In the United States, the company is recognized as the fifth largest\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142550,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-ltd-nseauropharma-q3fy23-results-out-total-income-rise-7-yoy\/","url_meta":{"origin":128324,"position":3},"title":"Earnings | Aurobindo Pharma Ltd. (NSE:AUROPHARMA): Q3FY23 Results Out; Total Income rise 7% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Aurobindo Pharma Ltd. (NSE:AUROPHARMA) is a global pharmaceutical company headquartered in India. The company produces and sells a wide range of generic pharmaceutical products and active pharmaceutical ingredients (APIs) in over 150 countries. Aurobindo Pharma's portfolio includes antibiotics, anti-retrovirals, anti-inflammatory drugs, cardiovascular drugs, and more. The company operates manufacturing facilities\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":147899,"url":"https:\/\/alphastreet.com\/india\/alphagraph-aurobindo-pharma-ltd-nse-auropharma-q4fy23-results-out-total-income-rises-13-yoy\/","url_meta":{"origin":128324,"position":4},"title":"Alphagraph | Aurobindo Pharma Ltd (NSE: AUROPHARMA): Q4FY23 Results Out; Total Income rises 13% YoY.","author":"Divyansh_Kasana","date":"May 31, 2023","format":false,"excerpt":"Aurobindo Pharma is a leading pharmaceutical company primarily involved in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company specializes in the production of APIs, which are the key components of pharmaceutical formulations. Aurobindo Pharma also focuses on the development, manufacturing, and distribution\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169833,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q1-fy26-earnings-results-revenue-up-4-net-profit-falls-10-yoy\/","url_meta":{"origin":128324,"position":5},"title":"Aurobindo Pharma Ltd Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 6, 2025","format":false,"excerpt":"Aurobindo Pharma Limited is a key player in the pharmaceutical industry. It manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company supports global healthcare with a broad product portfolio that serves both developed and emerging markets. Financial Highlights In Q1 FY26, Aurobindo Pharma reported revenue\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1796"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=128324"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128324\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=128324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=128324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=128324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}